AI-treated patients with ER+ tumors and any C-allele of CYP1A2 rs762551 genotype (n = 103) had a significantly higher risk for early breast cancer events versus the patients with A/A genotype (Fig. 2a; adjusted HR 2.22 (95 % CI 1.03–4.80). This evidence concerns the gene ESR1 and breast carcinoma.